Yu-Waye Chu Intends to Resign as Chief Medical Officer of Fate Therapeutics, Inc. Effective as of July 14, 2023
June 08, 2023 at 04:12 pm EDT
Share
Dr. Yu-Waye (Wayne) Chu, M.D. notified Fate Therapeutics, Inc. that he intends to resign as Chief Medical Officer of the Company effective as of July 14, 2023 to pursue another opportunity. Dr. Chus resignation is not associated with, or attributable to, any disagreement with the Company or the Company's
operations, policies, or practices.
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders. Its proprietary induced pluripotent stem cells (iPSC) product platform combines multiplexed-engineering of human iPSCs with single-cell selection to create clonal master iPSC lines. The Companyâs platform is designed to overcome numerous limitations associated with the manufacture of cell therapies using patient- or donor-sourced cells. Utilizing its proprietary iPSC product platform, it is advancing off-the-shelf, multiplexed-engineered natural killer (NK) cell and T-cell product candidates which are selectively designed, incorporate novel synthetic controls of cell function. Its pipeline of iPSC-derived, chimeric antigen receptor (CAR)-targeted NK cell and T-cell product candidates include FT819, FT522, FT576, FT825, FT819, FT522, and others.
FATE THERAPEUTICS, INC. 
